ArticleResearch square2023
Repurposing niclosamide as a novel anti-SARS-Cov-2 drug by restricting entry protein CD147.
Zhe Yang, Qi Zhang, Xiaoqing Wu, Siyuan Hao, Xinbao Hao, Elizabeth Jones, Yuxia Zhang, Jianming Qiu, Liang Xu
Open access · greenAbstract readPreprint
In one paragraphArticle in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 3 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
9 authors at 2 institutions in 1 country.
Zhe YangThe University of Kansas.
Qi ZhangThe University of Kansas.
Xiaoqing WuThe University of Kansas.
Siyuan HaoThe University of Kansas Medical Center.
Xinbao HaoThe University of Kansas.
Elizabeth JonesThe University of Kansas Medical Center.
Yuxia ZhangThe University of Kansas Medical Center.
Jianming QiuThe University of Kansas Medical Center.
Liang XuThe University of Kansas.
University of Kansas · USUniversity of Kansas Medical Center · US
Funding
Nano-Engineered Lab-on-a-Chip for Assessing HuR-Regulated Exosomes for Cancer Monitoring and Targeted TherapyR01CA243445 · NCI · UNIVERSITY OF KANSAS LAWRENCE · PI DIXON, DAN ALAN, XU, LIANG · 2019 to 2023
$3.0MMolecular cancer therapy targeting HuR-ARE interactionR01CA191785 · NCI · UNIVERSITY OF KANSAS LAWRENCE · PI AUBE, JEFFREY, XU, LIANG · 2015 to 2019
$2.1MRNA-binding protein HuR in liver pathophysiology and carcinogenesisR01DK119131 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ZHANG, YUXIA · 2019 to 2023
$1.8MNovel therapeutic strategy for renal fibrosis by targeting RNA-binding protein HuRR01DK123727 · NIDDK · UNIVERSITY OF UTAH · PI HUANG, YUFENG · 2020 to 2024
$1.8MIntegrative Functional Profiling of Tumor-Derived Extracellular VesiclesR33CA252158 · NCI · UNIVERSITY OF FLORIDA · PI XU, LIANG, ZENG, YONG · 2021 to 2024
$1.0MNCI NIH HHS R01 CA191785NCI NIH HHS R01 CA243445NCI NIH HHS R33 CA252158NIDDK NIH HHS R01 DK119131NIDDK NIH HHS R01 DK123727
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Identifiers
PMID37090542
PMCPMC10120763
OpenAlexW4365460361
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390